Search

Search Constraints

You searched for: Author/Creator Labianca, R.

Search Results

1. Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study. Issue 164 (April 2018)

2. LBA23FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. (18th September 2017)

3. 2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with "non diffusive type" gastric carcinoma radically resected. (September 2015)

4. PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer. Issue 213 (May 2022)

5. OC-1a: A prospective study of hemostatic biomarkers to predict early recurrence in high-risk breast cancer women undergoing post-surgical adjuvant systemic therapy. Issue 151 (March 2017)

6. Thrombin generation predicts for early recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: results from the HYPERCAN study. Issue 164 (April 2018)

7. PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy. Issue 200 (April 2021)

8. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (May 2021)

9. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer. Issue 4 (July 2016)

10. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Issue 3 (September 2015)